Trazodone News
Acute Pisa Syndrome and Pharnygolaryngeal Dystonia Due to Ziprasidone
Case Report: Mr. A, a 20-year-old Caucasian male, was admitted for exacerbation of schizoaffective disorder.
Labopharm Phase III Trial with Trazodone Hits Mark
After more than a year of FDA appeals regarding its once-daily formulation of the analgesic tramadol, Labopharm Inc. got some good news regarding its second product candidate, a once-daily formulation of the antidepressant...
TSX climbs heading into weekend
The S&P/TSX Composite was up 63.97 points or 0.49% to 12989.34 on Friday.
Labopharm enters into agreement for US$25 million debt financing
Labopharm Inc. today announced that, through its U.S. subsidiary, it has entered into an agreement for a US$25 million debt financing with US-based Hercules Technology Growth Capital, Inc. Proceeds from the financing will be used...
Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Labopharm Inc. today announced that it has completed patient enrolment in its North American Phase III clinical trial for its once-daily formulation of the antidepressant trazodone (study 04ACL3-001). More than 400 patients have...